Ruane, Cunniff & Goldfarb Inc. Reports Holdings in Valeant Pharmaceuticals International, Inc.

NEW YORK, NEW YORK--(Marketwired - May 31, 2013) - Ruane, Cunniff & Goldfarb Inc. ("RC&G") has filed an alternative monthly report regarding its holdings in Valeant Pharmaceuticals International, Inc. (the "Issuer").

As of May 31, 2013, the accounts over which RC&G has investment authority (collectively, the "Accounts") held 34,702,755 common shares of the Issuer, representing a securityholding percentage, calculated in accordance with National Instrument 62-103 The Early Warning System and Related Take-Over Bid and Insider Reporting Issues of approximately 11.42%.

RC&G held on behalf of the Accounts greater than 10% of the outstanding common shares of Valeant Pharmaceuticals International prior to its September 28, 2010 acquisition by the Issuer. As of September 30, 2010, RC&G held on behalf of the Accounts approximately 34,059,000 common shares of the Issuer, corresponding to a securityholding percentage of approximately 11.17%. RC&G's holdings in the Issuer have been reported in filings with the Securities and Exchange Commission and in management information circulars of the Issuer on an ongoing basis, but an alternative monthly report was not filed on SEDAR in 2010. This is the initial alternative monthly report filed by RC&G.

The securities of the Issuer are held for investment purposes. Depending upon the circumstances, RC&G may, from time to time and on behalf of the Accounts, acquire additional securities or related financial instruments of the Issuer or dispose of all or a portion of the securities or related financial instruments of the Issuer previously acquired.

Additional information is provided in the alternative monthly report filed on www.sedar.com.